The management of chronic myeloid leukaemia--a case history.
Sureda
A
A
Department of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Hernández-Bronchud
M
M
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002066:Busulfan / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D012074:Remission Induction; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D016898:Interferon-alpha; D016044:Fusion Proteins, bcr-abl; D002066:Busulfan; D006918:Hydroxyurea